Cardiff Oncology, Inc. (CRDF) was founded in 1999, formerly known as Trovagene, Inc. (formerly NASDAQ:TROV) was changed to its current name in May 2020, and then formerly known as Xenomics, Inc., in January 2010 Changed to Trovagene, headquartered in San Diego, California, with 12 full-time employees. It is a clinical-stage precision medicine oncology company that develops cancer treatment by using its proprietary precision cancer monitoring (PCM) technology in tumor genomics Oncology treatment methods.
Cardiff Oncology, Inc. (CRDF):
Cardiff Oncology, Inc. is a clinical-stage oncology treatment company dedicated to developing drugs for the treatment of various types of cancer, including leukemia, lymphoma and solid tumors.
Cardiff Oncology’s main drug candidate is onvansertib (PCM-075), a Polo-like kinase 1 selective adenosine triphosphate competitive inhibitor. It is currently in phase Ib/II clinical trials for acute myeloid leukemia (AML) and has Completed phase I clinical trials for advanced solid tumors; at the same time, it is in phase Ib/II clinical trials in combination with FOLFIRI and Avastin for metastatic colorectal cancer.
At the same time, Cardiff Oncology’s onvansertib is also being used in combination with Zytiga in a phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; a phase I clinical trial for the combined use of multiple chemotherapy and targeted therapies, such as Beleodaq (Belinostat); Quizartinib (AC220), a developing FLT3 inhibitor; Velcade (bortezomib) for leukemia, lymphoma and solid tumor cancer.
Cardiff Oncology, Inc. mainly serves pharmaceutical companies and third-party laboratories.
Cardiff Oncology and Nektar Therapeutics conducted a research collaboration to treat metastatic colorectal cancer.